Beactica & Almac Ink Drug Discovery Pact

Sweden-based Beactica has entered into a deal with Almac Discovery, a division of the Almac Group, for drug discovery.

Swedish fragment-based drug discovery company Beactica has signed an agreement with Almac Discovery, a division of the Almac Group.

Under the terms of the agreement, Beactica will use its Sprint proprietary drug discovery platform to identify high-quality fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery.

Tim Harrison, vp of Medicinal Chemistry at Almac Discovery, said,"We plan to take projects to clinical proof of concept (or earlier) before out-licensing or partnering for further development."